{"id":"gsk1292263","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BTK is a key component of the B cell receptor signaling complex and plays a critical role in the activation of B cells. Inhibiting BTK has been shown to reduce the activity of B cells, which are involved in the development of certain types of cancer.","oneSentence":"GSK1292263 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:40:00.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mantle cell lymphoma"},{"name":"Marginal zone lymphoma"}]},"trialDetails":[{"nctId":"NCT01218204","phase":"PHASE2","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-14","conditions":"Dyslipidaemias, Dyslipidemias","enrollment":287},{"nctId":"NCT01119846","phase":"PHASE2","title":"A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-05","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT01128621","phase":"PHASE2","title":"A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-23","conditions":"Diabetes Mellitus, Type 2","enrollment":66},{"nctId":"NCT00783549","phase":"PHASE1","title":"A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-04","conditions":"Dyslipidaemias","enrollment":76},{"nctId":"NCT01101568","phase":"PHASE1","title":"A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04-14","conditions":"Diabetes Mellitus, Type 2","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GSK1292263","genericName":"GSK1292263","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK1292263 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. Used for Mantle cell lymphoma, Marginal zone lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}